Back
Addus HomeCare 10K Form
Buy
51
ADUS
Addus HomeCare
Last Price:
124.28
Seasonality Move:
6.12%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2024-05-07 | 10Q | ADUS/Addus HomeCare Quarterly |
2023-10-31 | 10Q | ADUS/Addus HomeCare Quarterly |
2023-08-01 | 10Q | ADUS/Addus HomeCare Quarterly |
2023-05-02 | 10Q | ADUS/Addus HomeCare Quarterly |
2022-11-01 | 10Q | ADUS/Addus HomeCare Quarterly |
2022-08-02 | 10Q | ADUS/Addus HomeCare Quarterly |
Receive ADUS News And Ratings
See the #1 stock for the next 7 days that we like better than ADUS
ADUS Financial Statistics
Sales & Book Value
Annual Sales: | $1.06B |
---|---|
Cash Flow: | $46.59M |
Price / Cash Flow: | 16.59 |
Annual Sales: | $52.26 |
Price / Book: | 2.38 |
Profitability
EPS (TTM): | 4.37000 |
---|---|
Net Income (TTM): | $73.65M |
Gross Margin: | $339.88M |
Return on Equity: | 9.24% |
Return on Assets: | 6.89% |
Addus HomeCare Earnings Forecast
Key Addus HomeCare Financial Ratios
- The Gross Profit Margin over the past 17 years for ADUS is 32.10%.
- The Selling, General & Administrative Expenses for ADUS have been equal to 22.18% of Gross Profit Margin.
- The Research & Development expenses have been 0.00% of Revenue.
- The Interest Expense is 17.77% of Operating Income.
- The Net Earning history of ADUS is 5.91% of Total Revenues.
- Per Share Earnings over the last 17 years have been positive in 11 years.
Addus HomeCare Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Health Care Providers & Services |
Sector: | Health Care |
Current Symbol: | ADUS |
CUSIP: | 006739 |
Website: | addus.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 2.11 |
Quick Ratio: | 2.03 |
Price-to-Earnings
Trailing P/E Ratio: | 32.46 |
---|---|
Forward P/E Ratio: | 20.56 |
ADUS Technical Analysis vs Fundamental Analysis
Buy
51
Addus HomeCare (ADUS)
is a Buy
Is Addus HomeCare a Buy or a Sell?
-
Addus HomeCare stock is rated a Buy
The current Addus HomeCare [ADUS] share price is $124.32. The Score for ADUS is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.